Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic bone marrow-derived mesenchymal stem cells (Badiavas)
- Development stage
- Unknown
- Lead developer
- University of Miami
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Subcutaneous, Topical
01
Overview
This investigational cell therapy involves allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) for the treatment of deep second-degree burn wounds. Developed by Dr. Evangelos V. Badiavas and colleagues at the University of Miami, the therapy utilizes donor-derived stem cells to accelerate wound closure and improve regenerative outcomes. The mechanism of action is multifaceted, involving the secretion of paracrine factors that stimulate fibroblast proliferation, promote angiogenesis, and modulate the host's immune response to optimize the healing environment. Clinical studies have evaluated the therapy at multiple dose levels, administered via subcutaneous injection or topical application under a transparent film dressing. Early-phase results have demonstrated 100% wound closure with minimal fibrosis and evidence of re-pigmentation and hair follicle restoration.
- Other names
- allogeneic BM-MSCsallogeneic mesenchymal stem cellsallogeneic bone marrow mesenchymal stem cells
Beyond the preview
Go deeper on allogeneic bone marrow-derived mesenchymal stem cells (Badiavas).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic bone marrow-derived mesenchymal stem cells (Badiavas).